Analysis of the mechanism of antinociceptive action of niga-ichigoside F1 obtained from Rubus imperialis (Rosaceae).
We have previously verified that niga-ichigoside F(1) (NI), a triterpene isolated from Rubus imperialis, exhibits significant and potent antinociceptive action when evaluated in some pharmacological models of pain in mice. This effect was confirmed in other experimental models and also the mechanism of action has been evaluated. The antinociception caused by NI (60 mg kg(-1)) in both phases of the formalin test was significantly attenuated by intraperitoneal injection of mice with haloperidol (a dopaminergic antagonist, 0.20 mg kg(-1)) and L-arginine (precursor of nitric oxide, 600 mg kg(-1)). Regarding the cholinergic system, atropine (a cholinergic antagonist 60 mg kg(-1)) reverted only the second phase. The effect of NI was not affected by treatment of mice with yohimbine (an alpha2-adrenoceptor antagonist, 0.15 mg kg(-1)). The same pharmacological profile was observed for the administration of naloxone (an opioid receptor antagonist, 1 mg kg(-1)). On the other hand, intraperitoneal injection caused dose-related and significant effects against glutamate- and capsaicin-induced pain, respectively. In conclusion, the marked antinociception of NI appears to be related to the dopaminergic, cholinergic, glutamatergic, tachykininergic and oxinitrergic systems, supporting the ethnomedical use of Rubus imperialis (Rosaceae).
Ardenghi
Juliana Vargas
JV
Programa de Mestrado em Ciências Farmacêuticas e Núcleo de Investigações Químico-Farmacêuticas (NIQFAR)/CCS, Universidade do Vale do Itajaí (UNIVALI), 88302-202, Itajaí-SC, Brazil.
Kanegusuku
Márcia
M
Niero
Rivaldo
R
Filho
Valdir Cechinel
VC
Monache
Franco Delle
FD
Yunes
Rosendo Augusto
RA
De Souza
Márcia Maria
MM
D000700:Analgesics / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D002211:Capsaicin / Q000008:administration & dosage / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D018698:Glutamic Acid / Q000008:administration & dosage / Q000633:toxicity; D006220:Haloperidol / Q000008:administration & dosage / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D015394:Molecular Structure; D009020:Morphine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D019335:Nitroarginine / Q000494:pharmacology; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control; D010147:Pain Measurement / Q000379:methods; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology; D027824:Rosaceae / Q000737:chemistry*; D012503:Saponins / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D015016:Yohimbine / Q000494:pharmacology
D000700:Analgesics; D010936:Plant Extracts; D012503:Saponins; D019335:Nitroarginine; D015016:Yohimbine; D009270:Naloxone; D018698:Glutamic Acid; D009020:Morphine; D001285:Atropine; C090725:niga-ichigoside F1; D006220:Haloperidol; D001058:Apomorphine; D002211:Capsaicin